Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP)-RFA-CE22-002, Grants To Support New Investigators in Conducting Research Related To Preventing Interpersonal Violence Impacting Children and Youth; Amended Notice of Meeting, 12710-12711 [2022-04680]
Download as PDF
<![CDATA[
khammond on DSKJM1Z7X2PROD with NOTICES
12710
Federal Register / Vol. 87, No. 44 / Monday, March 7, 2022 / Notices
Purpose: The establishment and
formation of the HEW is to provide
input to the ACD, CDC on agency-wide
activities related to the scope and
implementation of CDC’s CORE (an
acronym for C-cultivate comprehensive
health equity science, O-optimize
interventions, R-reinforce and expand
robust partnerships, and E-enhance
capacity and workforce diversity and
inclusion) strategy around health equity.
The HEW membership will be
comprised of approximately 15
members. It will be chaired by two
current ACD, CDC Special Government
Employees. HEW co-chairs will present
their findings, observations, and work
products at one or more ACD, CDC
meetings for discussion, deliberation,
and decisions (final recommendations
to CDC).
Nomination Criteria: HEW members
will serve terms ranging from six
months to one year and be required to
attend HEW meetings approximately 1–
2 times per month (virtually or inperson), and contribute time in between
meetings for research, consultation,
discussion, and writing assignments.
Nominations are being sought for
individuals who have the expertise and
qualifications necessary to contribute to
the accomplishments of the
committee’s/workgroup’s objectives.
Nominees will be selected based on
expertise in the fields of health equity;
public health science and practice;
public health policy development,
analysis, and implementation. To
ensure a diverse workgroup
composition, nominees with front line
and field experience at the local, state,
tribal and territorial levels are
encouraged to apply. This includes
nominees with experience working for,
and with, community-based
organizations and other non-profit
organizations. Federal employees will
not be considered for membership.
Selection of members is based on
candidates’ qualifications to contribute
to the accomplishment of the HEW’s
objectives.
HHS policy stipulates that
membership be balanced in terms of
points of view represented and the
workgroup’s function. Appointments
shall be made without discrimination
based on age, race, ethnicity, gender,
sexual orientation, gender identity, HIV
status, disability, and cultural, religious,
or socioeconomic status. Nominees
must be U.S. citizens and cannot be fulltime employees of the U.S. Government.
Current participation on federal
workgroups or prior experience serving
on a federal advisory committee does
not disqualify a candidate; however,
HHS policy is to avoid excessive
VerDate Sep<11>2014
17:50 Mar 04, 2022
Jkt 256001
individual service on advisory
committees and multiple committee
memberships. Interested candidates
should submit the following items:
D A one-half to one-page cover letter
that includes your understanding of,
and commitment to, the time and work
necessary; one to two sentences on your
background and experience; and one to
two sentences on the skills/perspective
you would bring to the HEW.
D Current curriculum vitae which
highlights the experience and work
history being sought relevant to the
criteria set forth above, including
complete contact information
(telephone numbers, mailing address,
email address).
Nominations may be submitted by the
candidate him or herself, or by the
person/organization recommending the
candidate.
The Director, Strategic Business
Initiatives Unit, Office of the Chief
Operating Officer, Centers for Disease
Control and Prevention, has been
delegated the authority to sign Federal
Register notices pertaining to
announcements of meetings and other
committee management activities, for
both the Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Kalwant Smagh,
Director, Strategic Business Initiatives Unit,
Office of the Chief Operating Officer, Centers
for Disease Control and Prevention.
The meeting is being amended to
change the meeting date and should
read as follows:
CE22–003, Rigorously Evaluating
Programs and Policies to Prevent Child
Sexual Abuse (CSA): April 19, 2022.
The meeting is closed to the public.
FOR FURTHER INFORMATION CONTACT:
Aisha L. Wilkes, M.P.H., Scientific
Review Officer, National Center for
Injury Prevention and Control, CDC,
4770 Buford Highway NE, Mailstop
S106–9, Atlanta, Georgia 30341,
Telephone (404) 639–6473, AWilkes@
cdc.gov.
The Director, Strategic Business
Initiatives Unit, Office of the Chief
Operating Officer, Centers for Disease
Control and Prevention, has been
delegated the authority to sign Federal
Register notices pertaining to
announcements of meetings and other
committee management activities, for
both the Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Kalwant Smagh,
Director, Strategic Business Initiatives Unit,
Office of the Chief Operating Officer, Centers
for Disease Control and Prevention.
[FR Doc. 2022–04681 Filed 3–4–22; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[FR Doc. 2022–04690 Filed 3–4–22; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Disease, Disability, and Injury
Prevention and Control Special
Emphasis Panel (SEP)—CE22–003,
Rigorously Evaluating Programs and
Policies To Prevent Child Sexual
Abuse (CSA); Amended Notice of
Meeting
Notice is hereby given of a change in
the meeting of the Disease, Disability,
and Injury Prevention and Control
Special Emphasis Panel (SEP)—CE22–
003, Rigorously Evaluating Programs
and Policies to Prevent Child Sexual
Abuse (CSA), April 19–20, 2022, 8:30
a.m., EDT–5:30 p.m., EDT, Web
Conference, in the original FRN. The
meeting was published in the Federal
Register on January 14, 2022, Volume
87, Number 10, page 2439.
PO 00000
Frm 00055
Fmt 4703
Sfmt 4703
Disease, Disability, and Injury
Prevention and Control Special
Emphasis Panel (SEP)—RFA–CE22–
002, Grants To Support New
Investigators in Conducting Research
Related To Preventing Interpersonal
Violence Impacting Children and
Youth; Amended Notice of Meeting
Notice is hereby given of a change in
the meeting of the Disease, Disability,
and Injury Prevention and Control
Special Emphasis Panel (SEP)—RFA–
CE22–002, Grants to Support New
Investigators in Conducting Research
Related to Preventing Interpersonal
Violence Impacting Children and Youth,
March 8–9, 2022, 8:30 a.m., EDT–5:30
p.m., EDT, Web Conference, in the
original FRN. The meeting was
published in the Federal Register on
January 5, 2022, Volume 87, Number 3,
page 460.
The meeting is being amended to
change the meeting date and should
read as follows:
RFA–CE22–002, Grants to Support
New Investigators in Conducting
Research Related to Preventing
E:\FR\FM\07MRN1.SGM
07MRN1
Federal Register / Vol. 87, No. 44 / Monday, March 7, 2022 / Notices
Interpersonal Violence Impacting
Children and Youth: March 8, 2022.
The meeting is closed to the public.
FOR FURTHER INFORMATION CONTACT:
Aisha L. Wilkes, M.P.H., Scientific
Review Officer, National Center for
Injury Prevention and Control, CDC,
4770 Buford Highway NE, Mailstop
S106–9, Atlanta, Georgia 30341,
Telephone (404) 639–6473, AWilkes@
cdc.gov.
The Director, Strategic Business
Initiatives Unit, Office of the Chief
Operating Officer, Centers for Disease
Control and Prevention, has been
delegated the authority to sign Federal
Register notices pertaining to
announcements of meetings and other
committee management activities, for
both the Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Kalwant Smagh,
Director, Strategic Business Initiatives Unit,
Office of the Chief Operating Officer, Centers
for Disease Control and Prevention.
[FR Doc. 2022–04680 Filed 3–4–22; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Medicare & Medicaid
Services
[CMS–3425–N]
Announcement of the Approval of
COLA as an Accreditation
Organization for the Specialty of
Pathology To Include Histopathology,
Cytology and Oral Pathology Under the
Clinical Laboratory Improvement
Amendments of 1988
Centers for Medicare &
Medicaid Services (CMS), HHS.
ACTION: Notice.
AGENCY:
This notice announces the
application of COLA for approval as an
accreditation organization for clinical
laboratories under the Clinical
Laboratory Improvement Amendments
of 1988 (CLIA) program for the specialty
of Pathology to include Histopathology,
Cytology and Oral Pathology. We have
determined that COLA meets or exceeds
the applicable CLIA requirements. In
this notice, we announce the approval
and grant COLA deeming authority for
the specialty of Pathology to include
Histopathology, Cytology and Oral
Pathology for a period of 2 years.
DATES: This notice is effective from
March 7, 2022 to March 7, 2024.
FOR FURTHER INFORMATION CONTACT:
Raelene Perfetto (410) 786–6876.
khammond on DSKJM1Z7X2PROD with NOTICES
SUMMARY:
VerDate Sep<11>2014
17:50 Mar 04, 2022
Jkt 256001
SUPPLEMENTARY INFORMATION:
I. Background and Legislative
Authority
On October 31, 1988, the Congress
enacted the Clinical Laboratory
Improvement Amendments of 1988
(CLIA) (Pub. L. 100–578). CLIA
amended section 353 of the Public
Health Service Act. We issued a final
rule implementing the accreditation
provisions of CLIA on July 31, 1992 (57
FR 33992). Under those provisions,
CMS may grant deeming authority to an
accreditation organization if its
requirements for laboratories accredited
under its program are equal to or more
stringent than the applicable CLIA
program requirements in 42 CFR part
493 (Laboratory Requirements). Subpart
E of part 493 (Accreditation by a Private,
Nonprofit Accreditation Organization or
Exemption Under an Approved State
Laboratory Program) specifies the
requirements an accreditation
organization must meet to be approved
by CMS as an accreditation organization
under CLIA.
II. Notice of Approval of COLA for the
Specialty of Pathology To Include
Histopathology, Cytology and Oral
Pathology as an Accreditation
Organization
In this notice, we approve COLA as an
organization that may accredit
laboratories for purposes of establishing
their compliance with CLIA
requirements for the specialty of
Pathology to include Histopathology,
Cytology and Oral Pathology. We have
examined the initial COLA application
and all subsequent submissions to
determine its accreditation program’s
equivalency with the requirements for
approval of an accreditation
organization under subpart E of part
493. We have determined that COLA
meets or exceeds the applicable CLIA
requirements. We have also determined
that COLA will ensure that its
accredited laboratories will meet or
exceed the applicable requirements in
subparts H, I, J, K, M, Q, and the
applicable sections of R. Therefore, we
grant COLA approval as an accreditation
organization under subpart E of part
493, for the period stated in the DATES
section of this notice for the specialty of
Pathology and the subspecialties of
Histopathology, Cytology and Oral
Pathology. As a result of this
determination, any laboratory that is
accredited by COLA during the time
period stated in the DATES section of this
notice will be deemed to meet the CLIA
requirements for the specialty of
Pathology to include Histopathology,
Cytology and Oral Pathology, and
PO 00000
Frm 00056
Fmt 4703
Sfmt 4703
12711
therefore, will generally not be subject
to routine inspections by a State survey
agency to determine its compliance with
CLIA requirements. The accredited
laboratory, however, is subject to
validation and complaint investigation
surveys performed by CMS, or its
agent(s).
III. Evaluation of COLA’s Request for
Approval as an Accreditation
Organization Under CLIA for the
Specialty of Pathology To Include
Histopathology, Cytology and Oral
Pathology
The following describes the process
used to determine that COLA
accreditation program meets the
necessary requirements to be approved
by CMS and that, as such, CMS may
approve COLA as an accreditation
program with deeming authority under
the CLIA program. In reviewing these
materials, we reached the following
determinations for each applicable part
of the CLIA regulations:
A. Subpart E—Accreditation by a
Private, Nonprofit Accreditation
Organization or Exemption Under an
Approved State Laboratory Program
COLA submitted its mechanism for
monitoring compliance with all
requirements equivalent to conditionlevel requirements, a list of all its
current laboratories and the expiration
date of their accreditation, and a
detailed comparison of the individual
accreditation requirements with the
comparable condition-level
requirements. We have determined that
COLA policies and procedures for
oversight of laboratories performing
laboratory testing for the specialty of
Pathology to include Histopathology,
Cytology and Oral Pathology are
equivalent to those required under the
CLIA regulations in the matters of
inspection, monitoring proficiency
testing (PT) performance, investigating
complaints, and making PT information
available. COLA submitted
documentation regarding its
requirements for monitoring and
inspecting laboratories and describing
its standards regarding data
management, the inspection process,
procedures for removal or withdrawal of
accreditation, notification requirements
for laboratories out of compliance, and
accreditation organization resources. We
have determined that COLA’s
requirements for monitoring and
inspecting laboratories are equivalent to
those required under our regulations for
laboratories in the areas of data
management, the inspection process,
procedures for removal or withdrawal of
accreditation, notification requirements
E:\FR\FM\07MRN1.SGM
07MRN1
]]>Agencies
[Federal Register Volume 87, Number 44 (Monday, March 7, 2022)]
[Notices]
[Pages 12710-12711]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2022-04680]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Disease, Disability, and Injury Prevention and Control Special
Emphasis Panel (SEP)--RFA-CE22-002, Grants To Support New Investigators
in Conducting Research Related To Preventing Interpersonal Violence
Impacting Children and Youth; Amended Notice of Meeting
Notice is hereby given of a change in the meeting of the Disease,
Disability, and Injury Prevention and Control Special Emphasis Panel
(SEP)--RFA-CE22-002, Grants to Support New Investigators in Conducting
Research Related to Preventing Interpersonal Violence Impacting
Children and Youth, March 8-9, 2022, 8:30 a.m., EDT-5:30 p.m., EDT, Web
Conference, in the original FRN. The meeting was published in the
Federal Register on January 5, 2022, Volume 87, Number 3, page 460.
The meeting is being amended to change the meeting date and should
read as follows:
RFA-CE22-002, Grants to Support New Investigators in Conducting
Research Related to Preventing
[[Page 12711]]
Interpersonal Violence Impacting Children and Youth: March 8, 2022.
The meeting is closed to the public.
FOR FURTHER INFORMATION CONTACT: Aisha L. Wilkes, M.P.H., Scientific
Review Officer, National Center for Injury Prevention and Control, CDC,
4770 Buford Highway NE, Mailstop S106-9, Atlanta, Georgia 30341,
Telephone (404) 639-6473, [email protected].
The Director, Strategic Business Initiatives Unit, Office of the
Chief Operating Officer, Centers for Disease Control and Prevention,
has been delegated the authority to sign Federal Register notices
pertaining to announcements of meetings and other committee management
activities, for both the Centers for Disease Control and Prevention and
the Agency for Toxic Substances and Disease Registry.
Kalwant Smagh,
Director, Strategic Business Initiatives Unit, Office of the Chief
Operating Officer, Centers for Disease Control and Prevention.
[FR Doc. 2022-04680 Filed 3-4-22; 8:45 am]
BILLING CODE 4163-18-P
